2025
Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED‐AHF): A prospective, randomized, mechanistic study
Biegus J, Iwanek G, Testani J, Zymliński R, Fudim M, Guzik M, Gajewski P, Ponikowski P. Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED‐AHF): A prospective, randomized, mechanistic study. European Journal Of Heart Failure 2025 PMID: 40455066, DOI: 10.1002/ejhf.3708.Peer-Reviewed Original ResearchAcute heart failureProximal tubular sodium reabsorptionCo-primary endpointsTubular sodium reabsorptionNaCl groupEffective decongestionDiuretic therapyUrine outputSodium reabsorptionHeart failureCumulative dose of furosemideGlucose groupFractional excretion of lithiumDose of furosemideMedian urine outputAbsolute distal reabsorptionVolume replacement therapyExcretion of lithiumSingle-blind studyInfusion of NaClInhibition of proximal tubular sodium reabsorptionFurosemide doseFluid overloadCumulative doseDecongestive effect
2023
Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study
John T, Chellapandian D, Shah R, Gillespie S, Liu K, Xiang Y, Bhatia M, Chaudhury S, Eckrich M, Guilcher G, Jaroscak J, Kasow K, Krajewski J, Ngwube A, Olson T, Rangarajan H, Horan J, Krishnamurti L, Shenoy S, Abraham A, Stenger E. Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study. Blood 2023, 142: 4904. DOI: 10.1182/blood-2023-182532.Peer-Reviewed Original ResearchHematopoietic cell transplantationRejection-free survivalAnti-thymocyte globulinSickle cell diseaseRelated donor hematopoietic cell transplantationDonor hematopoietic cell transplantationBu/CyShorter hospital stayCumulative doseSevere GVHDHospital stayOverall survivalCell transplantationCell diseaseDay 5Grade III/IVBu/cyclophosphamideBu/FluUse of alemtuzumabKaplan-Meier methodCurrent clinical trialsRisk of rejectionSmall cohort sizeSevere clinical phenotypeConditioning chemotherapy
2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification
Trapani D, Franzoi M, Burstein H, Carey L, Delaloge S, Harbeck N, Hayes D, Kalinsky K, Pusztai L, Regan M, Sestak I, Spanic T, Sparano J, Jezdic S, Cherny N, Curigliano G, Andre F. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Annals Of Oncology 2022, 33: 702-712. PMID: 35550723, DOI: 10.1016/j.annonc.2022.03.273.Peer-Reviewed Original ResearchConceptsNon-inferiority clinical trialClinical trialsESMO classificationCancer treatmentPrecision Medicine Working GroupSingle-arm studyHealth system burdenOngoing clinical trialsShorter treatment durationLevel of evidenceEvidence-based criteriaQuality of lifePublic health expertsMedicine Working GroupStandard regimensCohort investigationWorking GroupCumulative doseTreatment modalitiesTreatment modulationPatient representativesTreatment durationIntermittent scheduleFinancial toxicityEvidence of reduction
2020
Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease
Kim TI, Kiwan G, Mohamedali A, Zhang Y, Mena-Hurtado C, Mojibian H, Guzman RJ, Ochoa Chaar CI. Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease. Journal Of Vascular Surgery 2020, 73: 911-917. PMID: 33038480, DOI: 10.1016/j.jvs.2020.08.146.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmputation, SurgicalCardiovascular AgentsCoated Materials, BiocompatibleDrug-Eluting StentsEndovascular ProceduresFemaleHumansLimb SalvageMaleMiddle AgedPaclitaxelPeripheral Arterial DiseaseProsthesis DesignRetreatmentRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeVascular PatencyConceptsPaclitaxel-coated devicesPeripheral artery diseaseCause of mortalityPCD useRisk of mortalityCumulative doseFemoropopliteal peripheral artery diseaseKaplan-Meier survival curvesLong-term mortalityPeripheral arterial diseaseCox regression analysisDrug-coated balloonsOutcome of treatmentDrug-eluting stentsMajor amputationPrimary patencyReintervention rateArtery diseaseArterial diseaseRandomized trialsOpen surgeryPresent studySingle institutionEndovascular interventionPatientsThe association of statins for secondary prevention with progression to diabetes in patients with prediabetic state after coronary artery bypass graft surgery: A retrospective cohort study
Poorhosseini H, Tavolinejad H, Aminorroaya A, Soleimani H, Aasham O, Jalali A, Mohammadi A, Beigi S, Sadeghian S, Bagheri J, Tajdini M. The association of statins for secondary prevention with progression to diabetes in patients with prediabetic state after coronary artery bypass graft surgery: A retrospective cohort study. Journal Of Diabetes And Its Complications 2020, 34: 107713. PMID: 32900589, DOI: 10.1016/j.jdiacomp.2020.107713.Peer-Reviewed Original ResearchConceptsCoronary Artery Bypass GraftingOccurrence of MACEPost-CABG patientsCumulative doseSecondary prevention of coronary artery diseaseSecondary preventionCoronary artery bypass graft surgeryPrevention of coronary artery diseaseArtery bypass graft surgeryFamily history of T2DMDoses of statinsTime of surgeryAssociation of statinsType 2 diabetes mellitusComposite of deathOccurrence of type 2 diabetes mellitusAdverse cardiovascular eventsBenefits of statinsBypass graft surgeryHistory of hypertensionHistory of T2DMArtery Bypass GraftingBody mass indexCoronary artery diseaseProgression to diabetesAssociation Between Cumulative Dose of Physical Therapy and Incidence of Hospital-Acquired and Ventilator-Associated Pneumonias Among Critically Ill Patients
Qi W, Murphy T, Doyle M, Ferrante L. Association Between Cumulative Dose of Physical Therapy and Incidence of Hospital-Acquired and Ventilator-Associated Pneumonias Among Critically Ill Patients. 2020, a3577-a3577. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3577.Peer-Reviewed Original ResearchReal-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin
Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, Atallah E. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 556-560.e2. PMID: 32291234, DOI: 10.1016/j.clml.2020.03.004.Peer-Reviewed Original ResearchConceptsB-cell acute lymphocytic leukemia patientsAcute lymphocytic leukemia patientsAllo-HCTLymphocytic leukemia patientsInotuzumab ozogamicinOverall survivalLeukemia patientsAllogeneic hematopoietic stem cell transplantationMinimal residual disease negativityHematopoietic stem cell transplantationCommon grade 3Efficacy of iNOHigher adverse eventsMedian overall survivalMulticenter cohort analysisVeno-occlusive diseaseDuration of responseStem cell transplantationOverall response rateINO initiationComplete remissionMedian durationAdverse eventsMedian ageCumulative dose
2019
The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).
Lustberg M, Pfeiffer P, Qvortrup C, Muro K, Bengtson M, Nittve M, Sonesson C, Nagahama F, Sonehara Y, Carlsson C. The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN). Journal Of Clinical Oncology 2019, 37: tps3616-tps3616. DOI: 10.1200/jco.2019.37.15_suppl.tps3616.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyChronic chemotherapy-induced peripheral neuropathyMetastatic colorectal cancerProportion of patientsFree survivalSafety endpointCumulative doseHigh-risk stage IIAdditional safety endpointsProgressive-free survivalCommon adverse eventsPlacebo-controlled studyDisease-free survivalOxaliplatin-induced neuropathyTreatment of patientsManganese superoxide dismutase activitySuperoxide dismutase mimeticFOLFOX6 chemotherapyMFOLFOX6 chemotherapyOXA treatmentPrimary endpointAdverse eventsFirst doseOverall survivalMS patientsThe Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN).
Pfeiffer P, Qvortrup C, Muro K, Lustberg M, Nagahama F, Sonehara Y, Bengtson M, Nittve M, Sonesson C, Carlsson C. The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN). Journal Of Clinical Oncology 2019, 37: tps722-tps722. DOI: 10.1200/jco.2019.37.4_suppl.tps722.Peer-Reviewed Original ResearchMetastatic colorectal cancerProportion of patientsFree survivalSafety endpointCumulative doseHigh-risk stage IIAdditional safety endpointsProgressive-free survivalCommon adverse eventsOxaliplatin-induced neuropathyDisease-free survivalPatient reported symptomsTreatment of patientsManganese superoxide dismutase activitySuperoxide dismutase mimeticFOLFOX6 chemotherapyMFOLFOX6 chemotherapyOXA treatmentPrimary endpointAdverse eventsFirst doseOverall survivalMS patientsPeripheral neuropathyTreatment breaks
2018
The Association Between Cannabinoids and Psychosis
Tikka S, D’Souza D. The Association Between Cannabinoids and Psychosis. 2018, 127-155. DOI: 10.1007/978-3-319-90365-1_14.Peer-Reviewed Original ResearchChronic psychotic disordersPsychotic disordersClinical interventionsPsychosis outcomesEmergency department visitsOnset of psychosisPotent synthetic cannabinoidCannabinoid receptor agonistsSignificant clinical interventionHigh rateDuration of intoxicationCannabinoid exposureDepartment visitsCumulative doseReceptor agonistCannabinoid hypothesisClinical significancePeriod of intoxicationCannabinoid productsCannabis useEarly onsetPsychosisPotency of cannabisCannabinoidsRecreational cannabis
2015
Association of Cumulative Dose of Haloperidol With Next-Day Delirium in Older Medical ICU Patients*
Pisani MA, Araujo KL, Murphy TE. Association of Cumulative Dose of Haloperidol With Next-Day Delirium in Older Medical ICU Patients*. Critical Care Medicine 2015, 43: 996-1002. PMID: 25746748, PMCID: PMC4400211, DOI: 10.1097/ccm.0000000000000863.Peer-Reviewed Original ResearchConceptsMedical ICU patientsNext-day deliriumTime-dependent confoundingICU patientsCumulative doseMedical ICUNonintubated patientsOdds ratioConfusion Assessment MethodTreatment of deliriumDose of haloperidolAge 60 yearsEfficacy of haloperidolRoute of administrationAcademic medical centerImportant clinical covariatesICU stayIntubated patientsClinical covariatesObservational studyHigher oddsMedical CenterDeliriumPatientsHaloperidolGhrelin Partially Protects Against Cisplatin-Induced Male Murine Gonadal Toxicity in a GHSR-1a-Dependent Manner1
Whirledge SD, Garcia JM, Smith RG, Lamb DJ. Ghrelin Partially Protects Against Cisplatin-Induced Male Murine Gonadal Toxicity in a GHSR-1a-Dependent Manner1. Biology Of Reproduction 2015, 92: 76, 1-11. PMID: 25631345, PMCID: PMC4367966, DOI: 10.1095/biolreprod.114.123570.Peer-Reviewed Original ResearchConceptsTesticular cell deathTesticular damageGonadal toxicityEpididymal weightGrowth hormone secretagogue receptorDose-dependent side effectsCisplatin-induced cachexiaTime of euthanizationHigh cumulative doseBody weight homeostasisCell deathCisplatin-induced testicular damageNovel therapeutic approachesGonadotoxin exposurePermanent azoospermiaGhrelin administrationSubsequent infertilityChemotherapeutic drug cisplatinChemotherapeutic regimensCisplatin administrationGhrelin actionWeight homeostasisCumulative doseIntraperitoneal administrationSecretagogue receptor
2014
Cardiotoxicity and Cardioprotection in Childhood Cancer
Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, Franco VI, Miller TL. Cardiotoxicity and Cardioprotection in Childhood Cancer. Acta Haematologica 2014, 132: 391-399. PMID: 25228565, DOI: 10.1159/000360238.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAnthracycline cumulative doseAdverse late effectsSignificant cardiovascular diseaseUse of dexrazoxaneLong-term cardioprotectionAnthracycline chemotherapyCardiovascular damageCardioprotective strategiesOncological efficacyCardiac damageBlack raceCumulative doseFemale sexRisk factorsChildhood cancerCardiotoxic effectsCardiovascular diseaseLate effectsHigh riskHigh doseGenetic predispositionCardiotoxicityYounger ageTrisomy 21Nutritional supplements
2012
Sedation practices in a cohort of critically ill patients receiving prolonged mechanical ventilation.
Karir V, Hough CL, Daniel S, Caldwell E, Treggiari MM. Sedation practices in a cohort of critically ill patients receiving prolonged mechanical ventilation. Minerva Anestesiologica 2012, 78: 801-9. PMID: 22475804.Peer-Reviewed Original ResearchConceptsCumulative doseMorphine equivalentsIll patientsMechanical ventilationSubstance abuseDecreased opioid useLow cumulative doseRetrospective cohort studyHigh cumulative dosesMajority of patientsAmount of sedativesPatient-specific factorsUse of sedativesLess frequent useLorazepam equivalentsSedative needsAdult patientsCohort studyOpioid usePatient characteristicsOpioid analgesicsCumulative dosesEthanol abuseSedation practicesAlcohol abuse
2011
Prevention of Shivering During Therapeutic Temperature Modulation: The Columbia Anti-Shivering Protocol
Choi HA, Ko SB, Presciutti M, Fernandez L, Carpenter AM, Lesch C, Gilmore E, Malhotra R, Mayer SA, Lee K, Claassen J, Schmidt JM, Badjatia N. Prevention of Shivering During Therapeutic Temperature Modulation: The Columbia Anti-Shivering Protocol. Neurocritical Care 2011, 14: 389-394. PMID: 21210305, DOI: 10.1007/s12028-010-9474-7.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-2 Receptor AgonistsAdultAgedAnticonvulsantsConscious SedationCritical CareDexmedetomidineDose-Response Relationship, DrugFemaleFeverGlasgow Coma ScaleHeart ArrestHumansHypothermia, InducedIntensive Care UnitsIntracranial HypertensionMagnesium SulfateMaleMeperidineMiddle AgedMonitoring, PhysiologicNarcoticsNeuromuscular Nondepolarizing AgentsPropofolProspective StudiesShiveringVecuronium BromideConceptsPatient daysNeurological intensive care unitAnti-shivering agentsTherapeutic temperature modulationTotal patient daysPrevention of shiveringDoses of propofolIntensive care unitBaseline demographic informationNew clinical problemsInduced normothermiaMethodsAll patientsYounger patientsCare unitCumulative doseHigh riskClinical problemPatientsTemperature modulating devicesMore interventionsShiveringBaseline interventionDemographic informationFirst agentYoung men
2009
Stochastic fate of p53-mutant epidermal progenitor cells is tilted toward proliferation by UV B during preneoplasia
Klein AM, Brash DE, Jones PH, Simons BD. Stochastic fate of p53-mutant epidermal progenitor cells is tilted toward proliferation by UV B during preneoplasia. Proceedings Of The National Academy Of Sciences Of The United States Of America 2009, 107: 270-275. PMID: 20018764, PMCID: PMC2806764, DOI: 10.1073/pnas.0909738107.Peer-Reviewed Original ResearchConceptsP53 mutationsNonmelanoma skin cancer incidenceSame cumulative doseSkin cancer incidenceUVB radiationUV-irradiated epidermisP53 tumor suppressor geneP53-mutant clonesCumulative doseCancer incidenceP53 mutant cellsHigh-intensity exposureMurine epidermisPreneoplastic clonesTumor suppressor geneProgenitor cellsExposure resultsPrecancerous cellsPreneoplastic cellsHuman epidermisB radiationClones of cells
2008
Comparison of Clinical Outcome According to the Duration of Corticosteroid Therapy in Childhood Henoch-Schönlein Purpura: a Bicentric Study
Lee S, Shin J, Lee C, Kim K. Comparison of Clinical Outcome According to the Duration of Corticosteroid Therapy in Childhood Henoch-Schönlein Purpura: a Bicentric Study. Childhood Kidney Diseases 2008, 12: 170-177. DOI: 10.3339/jkspn.2008.12.2.170.Peer-Reviewed Original ResearchDuration of corticosteroid therapyCorticosteroid therapyGroup ACumulative dose of prednisoloneDuration of steroid therapyDuration of steroid useIncidence of abdominal painHenoch Schonlein purpura(HSPIncidence of relapseComparison of clinical outcomesDose of prednisoloneWhite blood cell countDevelopment of nephritisHenoch-Schonlein purpuraBlood cell countDiagnosis of HSPSteroid therapyAbdominal painRenal involvementBicentric studyPlatelet countSteroid useCumulative doseAlbumin levelsClinical outcomes
1983
Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance
Choi B, Berger H, Schwartz P, Alexander J, Wackers F, Gottschalk A, Zaret B. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. American Heart Journal 1983, 106: 638-643. PMID: 6613807, DOI: 10.1016/0002-8703(83)90080-7.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionVentricular ejection fractionCongestive heart failureLeft ventricular performanceVentricular performanceEjection fractionAbnormal baselineHeart failureDoxorubicin therapyDoxorubicin cardiotoxicityRadionuclide angiocardiographyAbnormal left ventricular ejection fractionFinal left ventricular ejection fractionAntecedent cardiovascular diseaseSerial radionuclide studiesFirst-pass radionuclide angiocardiographyIdentification of patientsUse of doxorubicinSafe discontinuationThoracic radiationVentricular functionCancer patientsCumulative doseCardiovascular diseaseRadionuclide assessment
1982
Dose-response curves for predicting misonidazole-induced peripheral neuropathy.
Schwade J, Makuch R, Strong J, Glatstein E. Dose-response curves for predicting misonidazole-induced peripheral neuropathy. Journal Of The National Cancer Institute 1982, 66: 1743-50. PMID: 6288238.Peer-Reviewed Original ResearchConceptsPeripheral neuropathyLinear logistic regression analysisTotal cumulative doseLogistic regression analysisLogistic regression modelsDose-response curveCumulative AUCCumulative dosePlasma eliminationPlasma concentrationsNeuropathyLinear logistic regression modelPharmacokinetic parametersPharmacokinetic curveCancer treatmentToxic agentsRegression analysisAUCRegression modelsPatientsPharmacokineticsDoseMisonidazole
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply